Purpose: To analyse the mortality associated with intravitreal injections of bevacizumab for age-related macular degeneration (AMD) in patients previously diagnosed with stroke or transient ischaemic attack (TIA). Methods: We reviewed bevacizumab-treated AMD patients with a diagnosis of stroke or TIA prior to their first bevacizumab injection (n = 948). Those patients, na€ ıve to any anti-vascular endothelial growth factor (anti-VEGF) at the time of stroke/TIA, were then compared to age-and gender-matched patients who had a stroke/TIA at the same time and had never been exposed to anti-VEGF. Survival analysis was performed using adjusted Cox regression. The main outcome measure was survival. Adjusted variables were age, smoking, alcohol abuse, hypertension, diabetes mellitus, obesity, ischaemic heart disease, congestive heart failure and liver cancer. Results: Age and gender distribution of bevacizumab-treated patients and controls were similar (mean age: 83.4 versus 83.7 years, p = 0.3; 51.7% males versus 52.5% males, p = 0.7). The adjusted mortality in patients who received bevacizumab within 3 months after stroke/TIA was significantly different than in patients non-exposed to bevacizumab (OR = 6.92, 95%, CI 1.88-25.43, p < 0.01). Within 6 months after stroke/TIA, the difference in adjusted mortality showed a strong trend (OR = 2.00, 95%, CI 0.96-4.16, p = 0.064). Within 12 months, it was insignificant (OR = 1.30, 95%, CI 0.75-2.26, p = 0.348). Conclusion: We found increased mortality within three months after a cerebrovascular event in patients treated with bevacizumab for AMD compared to patients for whom there was no record of a prescription to any anti-VEGF agent.
Introduction
Intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment has revolutionized the management of many retinal conditions, including neovascular age-related macular degeneration (AMD). Ranibizumab and aflibercept are approved as ophthalmic therapies. Bevacizumab is a full-length humanized monoclonal IgG antibody of 149 kDa inhibiting all VEGF-A isoforms (Amadio et al. 2015) . Approved in 2004 by FDA for systemic use in the treatment of certain metastatic cancers, it is widely used offlabel as intravitreal therapy in neovascular AMD as its efficacy was demonstrated more than a decade ago (Michels et al. 2005; Avery et al. 2006) . Several lines of evidence point towards a systemic effect of those intravitreally injected agents (Avery 2014; Semeraro et al. 2015) . Reduced systemic VEGF level was demonstrated in patients receiving intravitreal anti-VEGF (Carneiro et al. 2012; Zehetner et al. 2013; Avery et al. 2014) . Intraocular injection of bevacizumab strongly decreases the VEGF serum concentration, to the extent that one month after the treatment VEGF serum level is only 23% of baseline (Matsuyama et al. 2010) . In a number of conditions, the effects of intravitreally injected bevacizumab have been reported in the fellow non-injected eye (Hosseini et al. 2012; Bakbak et al. 2013; Karaca et al. 2013; Hanhart et al. 2014; Brito et al. 2015) . Circulating VEGF protects vascular patency and integrity, and thus, a prolonged anti-VEGF treatment potentially increases the risk of thromboembolic events (Tunon et al. 2009; Lim et al. 2011) . Systemic administration of anti-VEGF agents is associated with an increased risk of cerebrovascular events in patients with cancer (Grivas et al. 2009; Ranpura et al. 2010; Seet et al. 2011; Hershman et al. 2013; Letarte et al. 2013; Seidel et al. 2013; Zuo et al. 2014) .
A meta-analysis of anti-VEGF agents for patients with diabetic macular oedema revealed a potentially increased risk for cerebrovascular accidents (Avery & Gordon 2016) . Diabetic patients treated for macular oedema may, however, not represent the ideal group to study the systemic effects of intravitreal injections, as diabetes is a multisystem disease, and this specific ocular complication is associated with an increased overall mortality (Hirai et al. 2008) . In this regard, patients suffering from neovascular AMD, a primarily ocular condition, may offer a better model to evaluate the systemic risks of intravitreal anti-VEGF injections.
Several prospective studies were conducted in order to compare bevacizumab to ranibizumab in the treatment of neovascular AMD, with safety issues as secondary outcomes. For instance, the IVAN study investigators found that, over two years, the risk of non-fatal stroke and transient ischaemic attack (TIA) was higher with ranibizumab than with bevacizumab use (Chakravarthy et al. 2013) . In this trial, adverse cerebrovascular events were more common when the treatment was administered discontinuously, what real-world evidence shows to be widespread practice (Madhusudhana et al. 2016) . In long-term retrospective studies, strokes are frequently mentioned as a reason for discontinued follow-up (Berg et al. 2017) . In a recent meta-analysis from six randomized controlled trials, comparing the effect of intravitreal injections of bevacizumab relative to ranibizumab over 1 and 2 years, it was found that approximately 25% more bevacizumab-treated participants than ranibizumab-treated participants experienced one or more serious nonocular adverse events. By 1 year, 0.39% of the patients receiving bevacizumab had a stroke (four trials), 0.35% a TIA (three trials). By 2 years, 1.25% had a stroke (two trials) and 0.34% a TIA (one trial) (Solomon et al. 2016 ). Care must be taken when considering those results, as it is admitted that those studies and meta-analyses are not powered enough to correctly assess systemic risks of anti-VEGF intravitreal injections (Thulliez et al. 2014) . Specifically, with regard to their exclusion criteria, they fail to determine which already diseased populations are at increased systemic risk. Most trials excluded patients with recent strokes.
In this study, we aimed to study the mortality associated with intravitreal injections of bevacizumab for AMD in patients previously diagnosed with stroke or TIA. On that purpose, considering baseline systemic conditions, we compared mortality in poststroke/ TIA patients, whether exposed to intravitreal bevacizumab or not to any anti-VEGF agent.
Materials and Methods

Data sources
This retrospective, population-based analysis accessed data from the electronic medical records of all individuals affiliated with Clalit Health Services The HMO maintains a chronic disease registry database that includes information collected from a variety of sources: primary care physician reports, medication-use files, hospitalization records and outpatient clinic records. The methods of registry acquisition and maintenance were described elsewhere (Rennert & Peterburg 2001) .
For all individuals included in the analysis, we extracted information from the registry regarding the following conditions, which have been reported to be more prevalent in patients with AMD and to be associated with increased mortality (Klein et al. 2004; Boberg-Ans et al. 2006; Ikram et al. 2012) : diabetes mellitus, hypertension, smoking, alcohol abuse, ischaemic heart disease, cerebrovascular disease, congestive heart failure, liver cancer and obesity.
Two fasting glucose measurements above 126 mg/dl or 2-hr postload glucose level >200 mg/dl were considered diagnostic for diabetes mellitus. Subjects who did not meet these criteria but who gave a history of diabetes prior to their acceptance in the HMO were also considered to have diabetes, as well as those who were on therapy with either oral antidiabetic agents or insulin during at least 2 months in the observation period. Hypertension was defined as systolic blood pressure >140 mmHg, diastolic blood pressure greater than 90 mmHg, as measured at least twice in the HMO. Subjects on antihypertensive drugs during at least 2 months in the observation period and those with a history of hypertension prior to joining the HMO were also included in this diagnostic group. Patients were categorized as smokers if they reported having smoked >100 cigarettes in their lifetime and currently smoked every day. The definitions in the HMO database of alcohol abuse are based on the diagnostic and statistical manual of mental disorders, version IV. Cerebrovascular disease was diagnosed following the criteria of the National Institute of Neurological Disorders (Grinnon et al. 2012) . The clinical data standards of the American College of Cardiology/American Heart Association Task Force were used to define congestive heart failure and ischaemic heart disease (Hicks et al. 2015) . A body mass index of 30 kg/m 2 of higher defined obesity.
Additional information extracted from patients' files included age, gender and socio-economic status. The date of death was automatically communicated from the Israeli Interior Ministry via the unique national identity number. The cause of death was not recorded.
Study population
In the nationwide Clalit Health Services records, we identified patients treated by anti-VEGF for AMD and excluded those for whom there was doubt regarding the indication of the treatment.
In the public health system in Israel, patients diagnosed with neovascular AMD are offered bevacizumab as a first-line agent. Patients who received other intraocular anti-VEGF agents (pegaptanib, ranibizumab, aflibercept) or systemic anti-VEGF therapy at any time were excluded from the analysis.
We selected bevacizumab-treated AMD patients with a diagnosis of stroke or TIA anytime prior to their first bevacizumab injection (n = 948). For each interval between stroke/TIA and first injection of bevacizumab, we generated a subgroup of patients. Fifteen patients had received bevacizumab within 3 months from stroke/TIA. Thirty-four had received bevacizumab within 6 months, 78 within 12 months and 157 within 24 months from stroke/ TIA.
Those patients were then compared to age-and gender-matched members of the HMO that had a stroke/TIA at the same time and had never been exposed to anti-VEGF. The nonexposed patients were members of the HMO in September 2008 and did not discontinue membership (for any reason, excepting death) till October 2014 (all poststroke/TIA subjects: n = 1494, within 3 months poststroke/TIA: n = 45; 6 months n = 82; 12 months n = 168; 24 months n = 290).
Statistical analysis
For all ratio variables, means and standard deviations were calculated and baseline differences between the groups negated using a t-test. For all nominal variables, absolute frequencies and percentages were calculated and baseline differences between the groups were negated using a chi-square test. The socio-economic ordinal variable baseline differences between the groups were negated using the Mann-Whitney Utest. Baseline socio-demographic and clinical characteristics of the case and the control groups are shown in Table 1 .
To compare mortality over time between the groups, survival analysis was performed using adjusted Cox regression. The dependent variable was survival. The time-dependent covariate for the treatment group (bevacizumab) was the interval between the first injection to survival or death, and for the reference group was the interval between the start of monitoring (date of first injection in the corresponding bevacizumab-treated patient) and survival or death, all truncated at 7 years. Adjusted variables were age, smoking, alcohol abuse, hypertension, diabetes, obesity, congested heart failure, liver cancer, ischaemic heart disease and cerebrovascular accident.
Statistical analyses were conducted using the SPSS statistical software (Version 20, IBM, Armonk, NY, USA). The criterion for accepting the research hypothesis (increased mortality in patients receiving bevacizumab as compared to the control group) was Alpha (a) = 0.05 (one-sided). The criterion for negating the preliminary differences between the treatment and the reference groups was Alpha (a) = 0.05 (twosided).
Results
A total of 2442 subjects were included in the study. Among this cohort, 948 received intravitreal injection of bevacizumab (the treatment group) and 1494 did not receive bevacizumab (the reference group).
Socio-demographic and clinical characteristics of the groups are shown in Table 1 . Bevacizumab-treated patients were slightly and insignificantly younger than controls (mean age: 83.4 versus 83.7 year, p = 0.3). The proportion of males was 51.7% in the treated group and 52.5% in the non-treated group (p = 0.7). A high prevalence of medical comorbidities was found in both groups. Univariate statistical tests were applied to the variables between the groups and adjustment performed in the Cox survival regression. For each interval between stroke/TIA and the first injection of bevacizumab, the adjusted Cox regression summaries are shown in Table 2 and the adjusted Cox regression survival are shown in Table 3 .
Within 3 months after stroke/TIA, 15 bevacizumab-treated patients were compared to 45 patients who did not receive bevacizumab. During the 73 months of follow-up, seven (47%) patients after bevacizumab died compared with two (22%) patients in the reference group (p < 0.001). After adjusted Cox survival regression, the mortality between the groups differed significantly, OR = 6.92 (95% CI 1.88-25.43, p < 0.01).
Within 6 months after stroke/TIA, 34 bevacizumab-treated patients were compared to 82 patients who did not receive bevacizumab. Fifteen (44%) bevacizumab-treated patients died compared with 20 (24%) patients in the reference group (p < 0.05). After adjusted cox survival regression, the mortality between the groups shows a strong trend, OR = 2.00 (95% CI 0.96-4.16, p = 0.064).
Within 12 months after stroke/TIA, 78 bevacizumab-treated patients were compared to 168 patients in the reference group. Twenty-two (28%) bevacizumab-treated patients died compared with 35 (21%) patients in the reference group (p = 0.255). The adjusted mortality between the groups was insignificant, OR = 1.30 (95% CI 0.75-2.26, p = 0.348).
The population within 24 months after stroke/TIA consisted of 157 bevacizumab-treated patients and 290 patients in the reference group. Forty (25%) bevacizumab-treated patients died compared with 54 (19%) patients in the reference group (p = 0.114). After adjusted cox survival regression, the mortality between the groups was insignificant, OR = 1.21 (95% CI 0.79-1.85, p = 0.371).
In our cohort, there were 948 patients who had suffered a stroke/ TIA anytime prior to bevacizumab injection. They were compared to 1494 patients from the reference group. A total of 285 (27%) bevacizumabtreated patients died compared with 253 (19%) patients in the reference group (p < 0.001). After adjusted Cox survival regression, the mortality between the groups differed significantly, OR = 1.44 (95% CI 1.27-1.61, p < 0.001). Figure 1 illustrates survival as a function of time in the bevacizumab-treated patients and controls for the whole studied population, while Fig. 2 (as well as Figs S1-S3) shows the difference between bevacizumab-treated patients and controls at various intervals between stroke/TIA and initiation of treatment.
Discussion
We report increased mortality within three months after a cerebrovascular event in patients treated with bevacizumab for neovascular AMD compared to patients for whom there was no record of a prescription to any anti-VEGF agent.
Patients after cerebrovascular events should be regarded as a high-risk population. Transient ischaemic attack (TIA) and stroke, particularly in the elderly, indicate in most cases a widespread cerebrovascular compromise, reflected by the risk of recurrence (Burn et al. 1994; Pendlebury & Rothwell 2009) , outstandingly increased in the few months after the initial attack (Giles & Rothwell 2007) . In the ischaemic brain, VEGF exerts an acute neuroprotective effect, as well as longer latency effects on survival of new neurons and on angiogenesis (Sun et al. 2003) . Through complex and not yet completely characterized mechanisms, VEGF therefore improves functional outcome from stroke (Croll & Wiegand 2001; Ayata et al. 2004; Lapi & Colantuoni 2015) .
Intravitreal injections of anti-VEGF agents decrease plasma VEGF level (Matsuyama et al. 2010; Carneiro et al. 2012; Zehetner et al. 2013; Avery et al. 2014) . The critical action of VEGF in the ischaemic brain explains why injections of anti-VEGF molecules in the vitreous worsen the prognosis of patients after stroke and TIA. In the SUSTAIN study, approximately 10% of patients with a history of a stroke suffered another stroke (Holz et al. 2011) . The SAILOR study also showed a higher risk of stroke in patients with a history of stroke who received ranibizumab compared to non-treated patients (Boyer et al. 2009 ). Bressler and coworkers analysed the risk of stroke in five randomized controlled trials evaluating ranibizumab in AMD and found that, when patients were stratified by their baseline risk of stroke, the subgroup with a high baseline risk had a sevenfold increase in the risk of stroke than controls (Bressler et al. 2012) . Among anti-VEGF compounds regularly used in AMD, bevacizumab seems to have the most significant effect on circulating VEGF (Matsuyama et al. 2010; Carneiro et al. 2012) .
To our knowledge, this is the first time that the systemic effect of intravitreally injected bevacizumab, a drug delivered off-label, is investigated in patients after stroke or TIA. The strength of this study is the inclusion of a large number of patients who received bevacizumab and no other anti-VEGF therapy for AMD, with the detailed registration of comorbidities and socio-economic data, which enabled suitable matching and multivariate analysis.
As a retrospective study that draws clinical data from an HMO database, this study has inherent weaknesses. However, it can be admitted that the HMO database was complete regarding the diagnoses and therapies: registration of ophthalmologic conditions is based on multiple visits; registration of chronic diseases is considered to be sufficiently solid (Rennert & Peterburg 2001) ; the HMO reimburses bevacizumab intraocular injections, given as first-line therapy (so there is benefit for patients to receive bevacizumab therapy outside the HMO). Fatal events would have been registered even for patients passing away after leaving the HMO. A limitation of this study is that our database does not differentiate between unilateral and bilateral injections and provides only limited information on ocular conditions. Visual acuity, for instance, is not recorded. Another weakness of our data is that the cause of death is not available. Nevertheless, all-cause mortality has some advantages as a principle endpoint, given the potential for misclassifying the cause of death (Gottlieb 1997 ).
On one hand, it would be technically and ethically difficult to prospectively isolate a sufficient amount of patients after recent stroke/TIA with active neovascular AMD, and randomly inject intraocular anti-VEGF agents or not, to reach statistical significance. Retrospective studies remain therefore the most adequate way to draw conclusions on the safety of intraocular injections in specific high-risk groups. On the other hand, if neovascular AMD had to be compared with non-neovascular AMD in order to retrospectivally analyse more similar cohorts, it would not be possible to ensure that the registration of dry AMD on that kind of database means it is truly non-neovascular, without even considering the issue of laterality. We therefore think that, despite its flaws, our methodology, taking into account known systemic risk factors associated with AMD, is appropriate to answer the sensitive question of bevacizumab safety in patients after stroke or TIA.
The benefits and risks should be taken into account when considering the treatment. These include systemic diseases and life expectancy as well as the expected treatment effect on the ability to function and quality of life (Tuuminen et al. 2017) . Our findings suggest that caution should be taken while offering bevacizumab to AMD patients within 6 months after stroke/ TIA. Anamnesis of patients diagnosed with neovascular AMD should consequently include neurologic history.
As bevacizumab is given as first-line therapy for neovascular AMD in Israel and mortality was found to be increased even years after the last bevacizumab injection, our data do not enable similar analysis for patients who received ranibizumab or aflibercept as second-and third-line agents. In countries using ranibizumab or aflibercept as first-line agents in AMD, data should be reviewed to assess the safety of those drugs in patients after stroke/IVA, with the registration of the cause of death if possible.
In view of our results, we advocate a precautionary approach for the treatment of other indications in which bevacizumab is currently used off-label, notably diabetic macular oedema, a condition known to be associated with an increased incidence of cerebrovascular events (Davis et al. 1999) . 
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